An observational study in Pediatric Growth Hormone Deficiency, sponsored by Fundació Sant Joan de Déu. Not yet recruiting at 5 sites in Spain. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Fundació Sant Joan de Déu · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.
Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.
Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.
Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.
Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.
Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.
Drug: Long-Acting Growth Hormone (LAGH)
Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.
Drug: Human recombinant growth hormone
LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Also known as: NGENLA, Somatrogon
Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Also known as: Somatropin, Genotonorm, Omnitrope, Norditropin
Change in Percentage Total Body Fat
Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.
Time frame: Baseline and 12 months
Change in Lean Body Mass
Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.
Time frame: Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.
Time frame: Baseline and 12 months
Change in height standard deviation score (SDS)
Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.
Time frame: Baseline and 12 months
Change in Waist Circumference
Change in waist circumference from baseline to 12 months, expressed in centimeters.
Time frame: Baseline and 12 months
Change in Waist-to-Hip Ratio
Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.
Time frame: Baseline and 12 months
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.
Time frame: Baseline and 12 months
Change in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.
Time frame: Baseline and 12 months
Change in Fasting Glucose Concentration
Change in fasting blood glucose concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Fasting Insulin Concentration
Change in fasting blood insulin concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in HOMA-IR
Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Total Cholesterol Concentration
Change in total cholesterol concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in LDL Cholesterol Concentration
Change in LDL cholesterol concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in HDL Cholesterol Concentration
Change in HDL cholesterol concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Triglyceride Concentration
Change in Triglyceride concentration from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.
Time frame: Baseline and 12 months
Change in Bone Mineral Density Z-Score
Change in bone mineral density Z-score measured by DXA from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Height Standard Deviation Score
Change in height standard deviation score (height SDS) from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
Change in growth velocity standard deviation score from baseline to 12 months.
Time frame: Baseline and 12 months
Change in Bone Age Minus Chronological Age
Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.
Time frame: Baseline and 12 months
Change in IGF-1 standard deviation score
Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.
Time frame: Baseline and 12 months
Plan to share: No — Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Sant Joan de Déu